Dietary anaplerotic therapy improves peripheral tissue energy metabolism in patients with Huntington's disease

European Journal of Human Genetics

Volumn 18, Issue 9, 2010, Pages 1057-1060

  Mochel, Fanny ^a,b   Duteil, Sandrine ^b,c   Marelli, Cécilia ^a   Jauffret, Céline ^b   Barles, Agnès ^b   Holm, Janette ^d   Sweetman, Lawrence ^d   Benoist, Jean François ^e   Rabier, Daniel ^f   Carlier, Pierre G ^b,c   Durr, Alexandra ^a,b  

^a INSTITUT DU CERVEAU ET DE LA MOELLE ÉPINIÈRE   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d BAYLOR UNIVERSITY MEDICAL CENTER   (United States)

^e HÔPITAL ROBERT DEBRÉ   (France)

^f HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

clinical trial; Huntington's disease; Krebs cycle; magnetic resonance spectroscopy; triheptanoin

Indexed keywords

SOMATOMEDIN C; TRIACYLGLYCEROL; TRIHEPTANOIN; UNCLASSIFIED DRUG;

ACIDOSIS; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; DIET THERAPY; DIETARY ANAPLEROTIC THERAPY; DRUG EFFICACY; DRUG TOLERABILITY; ENERGY METABOLISM; FEMALE; HUMAN; HUNTINGTON CHOREA; MALE; PH; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL;

BODY MASS INDEX; CITRIC ACID CYCLE; ENERGY METABOLISM; HUMANS; HUNTINGTON DISEASE; INSULIN-LIKE GROWTH FACTOR I; MAGNETIC RESONANCE SPECTROSCOPY;

EID: 77955984220     PISSN: 10184813     EISSN: 14765438     Source Type: Journal    
DOI: 10.1038/ejhg.2010.72     Document Type: Article

References (19)

1. Mochel F, Charles P, Seguin F et al: Early energy deficit in Huntington disease: identification of a plasma biomarker traceable during disease progression. PLoS One 2007; 2: e647.
2. De Bandt JP, Cynober L: Therapeutic use of branched-chain amino acids in burn, trauma, and sepsis. J Nutr 2006; 136: 308S-313S.
3. Roe CR, Mochel F: Anaplerotic diet therapy in inherited metabolic disease: therapeutic potential. J Inherit Metab Dis 2006; 29: 332-340.
4. Mochel F, DeLonlay P, Touati G et al: Pyruvate carboxylase deficiency: clinical and biochemical response to anaplerotic diet therapy. Mol Genet Metab 2005; 84: 305-312.
5. Duteil S, Bourrilhon C, Raynaud JS et al: Metabolic and vascular support for the role of myoglobin in humans: a multiparametric NMR study. Am J Physiol Regul Integr Comp Physiol 2004; 287: R1441-R1449.
6. Iotti S, Lodi R, Frassineti C, Zaniol P, Barbiroli B: In vivo assessment of mitochondrial functionality in human gastrocnemius muscle by 31P MRS. The role of pH in the evaluation of phosphocreatine and inorganic phosphate recoveries from exercise. NMR Biomed 1993; 6: 248-253.
7. Harris RA, Joshi M, Jeoung NH: Mechanisms responsible for regulation of branched-chain amino acid catabolism. Biochem Biophys Res Commun 2004; 313: 391-396.
8. Lodi R, Schapira AH, Manners D et al: Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. Ann Neurol 2000; 48: 72-76.
9. Saft C, Zange J, Andrich J et al: Mitochondrial impairment in patients and asymptomatic mutation carriers of Huntington's disease. Mov Disord 2005; 20: 674-679.
10. Laforet P, Wary C, Duteil S et al: [Exploration of exercise intolerance by 31P NMR spectroscopy of calf muscles coupled with MRI and ergometry]. Rev Neurol (Paris) 2003; 159: 56-67.
11. Zala D, Colin E, Rangone H, Liot G, Humbert S, Saudou F: Phosphorylation of mutant huntingtin at S421 restores anterograde and retrograde transport in neurons. Hum Mol Genet 2008; 17: 3837-3846.
12. Humbert S, Bryson EA, Cordelieres FP et al: The IGF-1/Akt pathway is neuroprotective in Huntington's disease and involves Huntingtin phosphorylation by Akt. Dev Cell 2002; 2: 831-837.
13. Cheng CM, Kelley B, Wang J, Strauss D, Eagles DA, Bondy CA: A ketogenic diet increases brain insulin-like growth factor receptor and glucose transporter gene expression. Endocrinology 2003; 144: 2676-2682.
14. Browne SE, Beal MF: The energetics of Huntington's disease. Neurochem Res 2004; 29: 531-546.
15. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D: Transcriptional repression of PGC-1alpha by mutant huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 2006; 127: 59-69.
16. Aziz NA, van der Burg JM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RA: Weight loss in Huntington disease increases with higher CAG repeat number. Neurology 2008; 71: 1506-1513.
17. Goodman AO, Murgatroyd PR, Medina-Gomez G et al: The metabolic profile of early Huntington's disease-a combined human and transgenic mouse study. Exp Neurol 2008; 210: 691-698.
18. van der Burg JM, Bacos K, Wood NI et al: Increased metabolism in the R6/2 mouse model of Huntington's disease. Neurobiol Dis 2008; 29: 41-51.
19. Zabel C, Mao L, Woodman B et al: A large number of protein expression changes occur early in life and precede phenotype onset in a mouse model for Huntington disease. Mol Cell Proteomics 2009; 8: 720-734.